Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-GD-2 scFv
- Development stage
- Preclinical
- Lead developer
- Charité Universitätsmedizin Berlin
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Anti-GD-2 scFv is a single-chain variable fragment (scFv) designed to target the ganglioside GD2, a surface antigen highly expressed on melanoma cells and other neuroectodermal tumors. Developed by researchers at Charité-Universitätsmedizin Berlin, this scFv is utilized as part of a multi-antigen panel (including CSPG-4 and MCAM) for the detection and isolation of circulating melanoma cells (CMCs) from blood samples. The scFv is produced in *E. coli*, biotinylated for streptavidin-based enrichment, and lacks the constant regions of full-length antibodies, allowing for efficient binding and isolation without compromising cell integrity. Its primary application is as a diagnostic or research tool for monitoring melanoma progression and treatment response.
- Other names
- anti-GD2 single-chain variable fragmentanti-GD-2 single-chain variable fragmentanti-GD 2 single-chain variable fragment
02
Targets
GD2GD3 (Ganglioside GD3)
Beyond the preview
Go deeper on anti-GD-2 scFv.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-GD-2 scFv.